Sclerostin serum levels in patients with systemic autoimmune
                        diseases

Fernández-Roldán, Concepción; Genre, Fernanda; López‐Mejías, Raquel; Ubilla, Begoña; Mijares, Verónica; Cano, Daniel Sánchez; Robles, Concepción López; Callejas-Rubio, José Luis; Fernández, Raquel Ríos; Ruíz, Manuela Expósito; Ortego-Centeno, Norbérto

doi:10.1038/bonekey.2016.2

Cited by 9 publications

(10 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, the sclerostin levels were significantly higher in our SLE patients than in controls. This result was inconsistent with that in the study of Fernández-Roldán et al, 14 the only available study conducted on SLE patients, who found that SLE patients did not differ from healthy controls regarding sclerostin levels. They conducted their study on a relatively smaller sample size and did not clarify the demography of their cohort 14 …”

Section: Discussioncontrasting

confidence: 98%

“…It was found to have a negative effect on bone mineral density (BMD) in postmenopausal women 41 . In SLE patients, Fernández-Roldán et al 14 showed a positive correlation between sclerostin levels and T and Z score values of BMD.…”

Section: Discussionmentioning

confidence: 99%

“…The serum sclerostin level and its implications were studied in limited numbers of SLE patients 14 . Antisclerostin monoclonal antibodies have emerged as a promising new approach for preventing fractures in women with postmenopausal osteoporosis, and it is possible to use such medications in SLE patients who have a significant risk of osteoporosis.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Measuring Serum Sclerostin in Egyptian Patients With Systemic Lupus Erythematosus and Evaluating Its Effect on Disease Activity

Soliman

Elgohary

2019

J Clin Rheumatol

View full text Add to dashboard Cite

ObjectiveSclerostin is an osteocyte-secreted protein that downregulates bone formation by blocking the Wnt/β-catenin signaling pathway. Sclerostin can be induced by inflammation, and high levels have been reported in patients with proteinuria and renal impairment. Studies evaluating the role of sclerostin in systemic lupus erythematosus (SLE) patients are scarce. This study aims to measure serum sclerostin in SLE patients and correlate its level with bone biomarkers and disease activity, particularly in lupus nephritis and arthritis. Finally, we evaluated factors that may predict sclerostin concentrations.MethodsThis cross-sectional, case-control study was conducted from May 2017 to April 2018. Serum sclerostin was measured by enzyme-linked immunosorbent assay in 100 SLE patients, including 50 patients with current lupus nephritis and 27 patients with current arthritis, as well as in 50 healthy controls. Correlation analysis of serum sclerostin with demography, bone biomarkers, and disease activity in SLE patients was carried out.ResultsSclerostin levels were significantly elevated in SLE patients, particularly those with lupus nephritis, compared with healthy controls. Higher levels were identified in patients without arthritis compared with those with; however, the former group had more proteinuria and renal impairment. Significant correlations were observed between sclerostin levels and serum creatinine, proteinuria, consumed C3 and C4 complement, and corrected Ca. Using multiple linear regression, proteinuria was the only significant predictor for serum sclerostin in SLE patients.ConclusionsThis study is the first to report that serum sclerostin is associated with proteinuria in SLE patients and could be used as a valuable biomarker for lupus nephritis.

show abstract

Section: Discussioncontrasting

confidence: 98%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Measuring Serum Sclerostin in Egyptian Patients With Systemic Lupus Erythematosus and Evaluating Its Effect on Disease Activity

Soliman

Elgohary

2019

J Clin Rheumatol

View full text Add to dashboard Cite

show abstract

“…In partial contrast, a study which evaluated changes in sclerostin levels following exogenous glucocorticoid initiation found no significant change in serum sclerostin levels after two months of therapy, but a slight increase in sclerostin levels relative to baseline when assessed at 12 months (P=0.045) [54]. In addition, in a heterogeneous population of patients with systemic autoimmune diseases, Fernandez-Roldan et al [55] found no effect of glucocorticoid treatment on serum sclerostin levels. Reasons for these seemingly discrepant results are unclear, although one potential explanation is that sclerostin measurements in the various studies were done using different assays.…”

Section: Hormonal Regulation Of Sclerostinmentioning

confidence: 99%

Hormonal and systemic regulation of sclerostin

Drake

Khosla

2017

Bone

View full text Add to dashboard Cite

The Wnt/β-catenin signaling pathway plays an essential role in osteoblast biology. Sclerostin is a soluble antagonist of Wnt/β-catenin signaling secreted primarily by osteocytes. Current evidence indicates that sclerostin likely functions as a local/paracrine regulator of bone metabolism rather than as an endocrine hormone. Nonetheless, circulating sclerostin levels in humans often reflect changes in the bone microenvironment, although there may be exceptions to this observation. Using existing assays, circulating sclerostin levels have been shown to be altered in response to both hormonal stimuli and across a variety of normal physiological and pathophysiological conditions. In both rodents and humans, parathyroid hormone provided either intermittently or continuously suppresses sclerostin levels. Likewise, most evidence from both human and animal studies supports a suppressive effect of estrogen on sclerostin levels. Efforts to examine non-hormonal/systemic regulation of sclerostin have in general shown less consistent findings or have provided associations rather than direct interventional information, with the exception of mechanosensory studies which have consistently demonstrated increased sclerostin levels with skeletal unloading, and conversely decreases in sclerostin with enhanced skeletal loading. Herein, we will review the existent literature on both hormonal and non-hormonal/systemic factors which have been studied for their impact on sclerostin regulation.

show abstract

“…Notably, they found that the SOST levels were lower than the baseline after 4 weeks. A recent study of patients with SLE, systemic sclerosis, and Crohn's disease revealed some heterogeneity in SOST levels between different autoimmune diseases . Thus, the discrepancies among recent studies may be partly due to nonlinear changes in SOST levels and the underlying diseases.…”

Section: Discussionmentioning

confidence: 99%

Serum Biomarkers Related to Glucocorticoid‐Induced Osteonecrosis of the Femoral Head: A Prospective Nested Case‐Control Study

Wang

Hua

Chang

et al. 2019

Journal Orthopaedic Research

View full text Add to dashboard Cite

Early diagnosis and prevention of glucocorticoid (GC)‐induced osteonecrosis of the femoral head (ONFH) continues to be a challenging problem for clinicians and researchers. However, the role of circulating biomarkers for GC‐induced ONFH, which may reveal individual susceptibility and facilitate earlier diagnosis, remains to be determined. The aim of this study was to identify potential biomarkers that may predict early GC‐induced ONFH. A total of 123 patients scheduled for initial systemic GC therapy were enrolled in this prospective nested case–control study. The serum concentrations of 13 potential biomarkers were measured in seven patients with GC‐induced ONFH, diagnosed instantly after short‐term use of GCs and in 20 controls who did not develop osteonecrosis despite similar GC therapy. Biomarkers were measured both before and after taking GCs to identify any differences in marker levels and the changes during GC therapy between two groups. Type I collagen cross‐linked C‐telopeptide (β‐CTX; p = 0.000) was significantly lower, high‐density lipoprotein cholesterol (p = 0.092) and apolipoprotein (apo)‐B/apo‐A1 (p = 0.085) tended to be lower and higher, respectively, before GC treatment in osteonecrosis group. After GC therapy, β‐CTX (p = 0.014) was significantly lower and amino terminal telopeptide of procollagen type I (PINP; p = 0.068) tended to be lower in the osteonecrosis group. As secondary outcomes, we observed remarkable changes in nine potential biomarkers following short‐term GC therapy in both groups. In conclusion, we found that β‐CTX, could potentially be used to predict GC‐induced ONFH before GC therapy. Lower β‐CTX and PINP are promising biomarkers for the early diagnosis of GC‐induced ONFH. These findings need to be confirmed in large‐scale prospective studies. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 37:2348–2357, 2019

show abstract

Sclerostin serum levels in patients with systemic autoimmune diseases

Cited by 9 publications

References 28 publications

Measuring Serum Sclerostin in Egyptian Patients With Systemic Lupus Erythematosus and Evaluating Its Effect on Disease Activity

Measuring Serum Sclerostin in Egyptian Patients With Systemic Lupus Erythematosus and Evaluating Its Effect on Disease Activity

Hormonal and systemic regulation of sclerostin

Serum Biomarkers Related to Glucocorticoid‐Induced Osteonecrosis of the Femoral Head: A Prospective Nested Case‐Control Study

Contact Info

Product

Resources

About